ANIP FY 2017 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

FY 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$177M+37.5% YoY

Gross Profit

$98M55.3% margin

Operating Income

$28M16.0% margin

Net Income

-$1M-0.6% margin

EPS (Diluted)

$-0.09

Cash Flow

Operating Cash Flow

$39M

Free Cash Flow

-$69M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$412M

Total Liabilities

$237M

Stockholders' Equity

$175M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$177M	$129M	+37.5%
Gross Profit	$98M	$80M	+22.5%
Operating Income	$28M	$20M	+41.1%
Net Income	-$1M	$4M	-127.4%